NSAID warning by FDA

the FDA just reinforced their existing warning label on the use of non-aspirin NSAIDs and the increased chance of heart attack or stroke (this warning is already on the over-the-counter ones). their comments:

--the risk of heart attack or stroke can occur within the first weeks of taking NSAIDs
--the risk is greater with higher doses
--although they acknowledge that newer information suggests some differences in NSAID risk, they do not feel it is sufficient to attribute either higher or lower risk to any individual agent
--the increased heart attack/stroke risk is not limited to those with known heart disease or increased risk factors form heart disease, though since their absolute risk is higher in general, they have greater risk of NSAID-induced heart attack or stroke
--those with known heart disease or risk factors are even more likely to die of a heart attack or stroke in the first year after their heart attack
--there is increased risk of heart failure with NSAIDs

those of you who have been reading these blogs for awhile know that I have real concerns about the overuse of a couple of drug classes in particular: PPIs and NSAIDs.  This link goes through some of the details from a Danish study -- http://gmodestmedblogs.blogspot.com/2015/03/nsaids-post-mi.html and includes some of the data suggesting that there are significant differences between the different NSAIDs. Though I use them quite sparingly, I think the data supporting naproxen over the others is pretty good. However, a large impetus to my doing lots of steroid injections, especially in the elderly, is to spare using systemic NSAIDs (this includes not just joint injections for OA, gout, pauciarticular RA, tendinitis, but I have also had great outcomes at time from injecting discrete back muscle spasms). I also use more topical drugs (topical capsaicin, diclofenac, lidocaine).

Comments

Post a Comment

if you would like to receive the near-daily emails regularly, please email me at gmodest@uphams.org

Popular posts from this blog

HDL a negative risk factor? or cholesterol efflux??

Although the data on HDL being protective of atherosclerotic disease is pretty consistent, there are negative studies, and the data on medications which dramatically improve HDL levels (eg, the cholesteryl ester transfer protein --CETP --inhibitors, such as torcetrapib) are clinically disappointing. there have been several explanations for this. for example, some HDL particles are "pro-inflammatory" and elicit an atherosclerotic response (which may be related to apolipoprotein C-III). a new article in NEJM highlights another angle -- that the issue is not the HDL number, but HDL's functionality in the reverse transport of cholesterol, as measured by the cholesterol efflux capacity (see  lipids HDL efflux capacity vs amt NEJM 2014 in dropbox, or  DOI: 10.1056/NEJMoa1409065). This article looks at the Dallas Heart Study, where they measured HDL levels, HDL particle concentrations, and cholesterol efflux capacity in 2924 adults free of cardiovascular disease and followed p
Read more

Drug company shenanigans: narcolepsy drug

I have not done a blog for a long time on drug company shenanigans. So it is my great pleasure to bring up a brand-new drug company approach to garner huge amounts of money (see  https://www.nytimes.com/2023/02/28/business/jazz-narcolepsy-avadel-patents.html?smid=nytcore-ios-share&referringSource=articleShare  ).  Based on an article by  Rebecca Robbins of the New York Times, who has written several articles on drug company excesses   As background, this will be my 42 nd  such blog: for the array, see  https://bucommunitymed.wpengine.com/page/4/?s=drug+company+shenanigans   Th e drug company  approach  this time  to extending  their  patents has a few “interesting” angles: -- this is a medication manufactured by Jazz Pharmaceuticals to treat narcolepsy: there are 2 versions: Xyrem and Xywav (Xywav has less sodium, so is marketed to those who should be on a low sodium diet). These meds are basically derivatives of gammahydroxybutyric acid (GHB)      -- the drug actually has a pretty
Read more

UPDATE: ASCVD risk factor critique

  I decided to do an extensive update of my prior ASCVD (atherosclerotic cardiovascular disease) risk analysis and critique of risk calculators, with much more information about the “non-traditional” risk factors. I felt that there should be more data/clarification, since I think we are really undertreating/not preventing the most common cause of death by relying on the ASCVD risk calculators   -- Cardiovascular risk models:      -- many of us rely on the various cardiovascular risk models to determine the appropriate approach to patients, and these are often integrated into the electronic medical records      -- these risk models have several very important limitations:          -- they are typically based on community data, eg from the Framingham study etc. But, in clinical practice, we are dealing with the individual and not the community:              -- there is very clear evidence that there are many individual risk factors that are associated with increased risk of a cardiovascu
Read more